<DOC>
	<DOCNO>NCT00261703</DOCNO>
	<brief_summary>Primary Objective : - Phase II : To determine best treatment scheme ( TPF vs. PF ) . - Phase III : To compare time progression treatment failure 3 arm . Secondary objective : - To evaluate safety 3 arm . - To compare progression , overall survival locoregional control 3 arm .</brief_summary>
	<brief_title>Docetaxel Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Head Neck cancer locally advance ( oral cavity , oropharynx , hypopharynx larynx ) without evident metastasis . Inoperable tumor revision multidisciplinary oncology team . Proved epidermoid carcinoma . ECOG = 01 Good hematologic function ( i.e , hemoglobin &gt; 10 g/dl , ... ) Good hepatologic function Good renal function Pregnant breastfeeding woman . Potential childbearing woman use effective conceptive method negative pregnancy test least week enter study . Nasopharynx , nasal cavity paranasal sinusitis exclude Previous chemotherapeutic radiotherapeutic treatment disease . Previous current neoplasms location , except situ cervicouterine cancer properly treat basal cell squamous cell carcinoma Symptomatic peripheral neuropathy Other clinical severe disease Concomitant treatment corticoid within 6 month prior inclusion . Concomitant treatment neoplastic therapy Previous treatment current disease . Loss weight great 10 % within last 3 month . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>